The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The clinical course of bone metastases from breast cancer
Open accessAbstract
All patients with carcinoma of the breast seen in this Unit since 1970 were reviewed to study the incidence, prognosis, morbidity and response to treatment of bone metastases. The biological characteristics of the primary tumour were compared in patients relapsing first in bone or liver. Sixty-nine percent of patients dying with breast cancer had bone metastases and bone was the commonest site of first distant relapse. Bone relapse was more common in receptor positive or well differentiated (grade 1) tumours. The median survival was 24 months in those with disease apparently confined to the skeleton compared with 3 months after first relapse in liver. Ten percent of patients with breast cancer developed hypercalcaemia. All had metastatic disease and 85% had widespread skeletal involvement. Fifteen percent of patients with disease confined to the skeleton developed hypercalcaemia. The response in bone to primary endocrine therapy, and chemotherapy, was apparently less than the overall response achieved. A large proportion had apparently static disease reflecting the insensitivity of the UICC assessment criteria. The duration of survival in these patients was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 705
Self-citationBone metastases and breast cancer
Coleman, R. E., & Rubens, R. D. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90008-8 · Cited by 97
Self-citationStewart, J. F., King, R. J. B., Hayward, J., & Rubens, R. D. (1982) · Breast Cancer Research and Treatment · doi:10.1007/bf01806937 · Cited by 41
Self-citation
Cited by
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Self-citationSkeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Self-citationFeng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3523 · Cited by 986
Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T., & Mundy, G. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118947 · Cited by 851
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Macedo, F., Ladeira, K., Pinho, F., Saraiva, N., Bonito, N., Pinto, L., & Gonçalves, F. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.321 · Cited by 775
Bone Imaging in Metastatic Breast Cancer
Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., & Ueno, N. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.181 · Cited by 656
Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain
Schwei, M. J., Honore, P., Rogers, S. D., Salak-Johnson, J. L., Finke, M. P., Ramnaraine, M. L., Clohisy, D. R., & Mantyh, P. W. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-24-10886.1999 · Cited by 516
Honore, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 498
Cox, T. R., Rumney, R. M. H., Schoof, E. M., Perryman, L., Høye, A. M., Agrawal, A., Bird, D., Latif, N. A., Forrest, H., Evans, H. R., et al. (2015) · Nature · doi:10.1038/nature14492 · Cited by 482
RetractedYoneda, T., Williams, P. J., Hiraga, T., Niewolna, M., & Nishimura, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1486 · Cited by 473
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Self-citationHennequin, L. F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T. P., Lambert-van der Brempt, C., Morgentin, R., Norman, R. A., Olivier, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060434q · Cited by 364
Bisphosphonates for breast cancer
Pavlakis, N., & Stockler, M. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474 · Cited by 360
Solomayer, E.-F., Diel, I. J., Meyberg, G. C., Gollan, C., & Bastert, G. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006308619659 · Cited by 359
Bruland, Ø. S., Nilsson, S., Fisher, D. R., & Larsen, R. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0841 · Cited by 357
Bisphosphonates and other bone agents for breast cancer
O'Carrigan, B., Wong, M. H., Willson, M. L., Stockler, M. R., Pavlakis, N., & Goodwin, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub4 · Cited by 356
Strategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
Saarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.10 · Cited by 341
Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy
Kozlow, W., & Guise, T. A. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-5399-8 · Cited by 337
Molecular mechanisms of osteolytic bone metastases
Guise, T. A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2892::aid-cncr2>3.0.co;2-y · Cited by 331
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
Aoudjit, F., & Vuori, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204554 · Cited by 325
A rat model of bone cancer pain
Medhurst, S. J., Walker, K., Bowes, M., Kidd, B. L., Glatt, M., Muller, M., Hattenberger, M., Vaxelaire, J., O'Reilly, T., Wotherspoon, G., et al. (2002) · Pain · doi:10.1016/s0304-3959(01)00437-7 · Cited by 311
Crosstalk between cancer cells and bone microenvironment in bone metastasis
Yoneda, T., & Hiraga, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.070 · Cited by 308
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307
3D Bioprinting a Cell-Laden Bone Matrix for Breast Cancer Metastasis Study
Zhou, X., Zhu, W., Nowicki, M., Miao, S., Cui, H., Holmes, B., Glazer, R. I., & Zhang, L. G. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10673 · Cited by 307
Biology of Osteoclast Activation in Cancer
Roodman, G. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3562 · Cited by 306
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Clinical course and prognostic factors following bone recurrence from breast cancer
Coleman, R., Smith, P., & Rubens, R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.52 · Cited by 293
Self-citationMartin, F. T., Dwyer, R. M., Kelly, J., Khan, S., Murphy, J. M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F. P., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0734-1 · Cited by 290
“The preferential spread of tumour cells to bone and subsequent development of osteolytic metastatic deposits remains a devastating event in the course of the disease [2, 3].”
BackgroundSchirrmeister, H., Guhlmann, A., Kotzerke, J., Santjohanser, C., Kühn, T., Kreienberg, R., Messer, P., Nüssle, K., Elsner, K., Glatting, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2381 · Cited by 283
Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone
Sloan, E. K., Pouliot, N., Stanley, K. L., Chia, J., Moseley, J. M., Hards, D. K., & Anderson, R. L. (2006) · Breast Cancer Research · doi:10.1186/bcr1398 · Cited by 275
Management of bone metastases in cancer: A review
Selvaggi, G., & Scagliotti, G. V. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.011 · Cited by 266
Friedel, G. (2002) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(02)00331-7 · Cited by 264
MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent
Zhou, Z., Qutaish, M., Han, Z., Schur, R. M., Liu, Y., Wilson, D. L., & Lu, Z.-R. (2015) · Nature Communications · doi:10.1038/ncomms8984 · Cited by 260
The bone microenvironment invigorates metastatic seeds for further dissemination
Zhang, W., Bado, I. L., Hu, J., Wan, Y.-W., Wu, L., Wang, H., Gao, Y., Jeong, H.-H., Xu, Z., Hao, X., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.011 · Cited by 260
Macedo, F. (2017) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2017.04.555637 · Cited by 257
Adipocyte biology in breast cancer: From silent bystander to active facilitator
Choi, J., Cha, Y. J., & Koo, J. S. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.11.002 · Cited by 255
Clines, G. A., & Guise, T. A. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00543 · Cited by 253
Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development
Luo, X., Fu, Y., Loza, A. J., Murali, B., Leahy, K. M., Ruhland, M. K., Gang, M., Su, X., Zamani, A., Shi, Y., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.016 · Cited by 141
“Indeed, nearly 80% of advanced breast cancer patients develop bone metastases (Coleman and Rubens, 1987).”
Mancino, A. T., Klimberg, V. S., Yamamoto, M., Manolagas, S. C., & Abe, E. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6204 · Cited by 138
Di Leo, A., O’Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0094-2 · Cited by 66
Use of bisphosphonates for the treatment of bone metastasis in experimental animal models.
Yoneda, T., Michigami, T., Yi, B., Williams, P. J., Niewolna, M., & Hiraga, T. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0133 · Cited by 52
Metadata
- Authors
- Coleman, R., & Rubens, R.
- Venue
- British Journal of Cancer
- Published
- 1987-01
- Volume
- 55
- Issue
- 1
- Pages
- 61-66
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2054351138
- Cited by
- 1,084
- References
- 4
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.